Favezelimab/pembrolizumab
Favezelimab/pembrolizumab is a combination therapy involving two immunotherapy drugs, Favezelimab and Pembrolizumab, used in the treatment of various types of cancer. This combination leverages the mechanisms of action of both drugs to enhance the immune system's ability to detect and destroy cancer cells. Favezelimab is an investigational drug targeting the SIGLEC-15 protein, while Pembrolizumab, marketed under the brand name Keytruda, is a well-established PD-1 inhibitor used in oncology.
Mechanism of Action[edit | edit source]
The mechanism of action for this combination therapy involves two distinct pathways aimed at enhancing the body's immune response against cancer cells. Pembrolizumab blocks the interaction between PD-1, a protein on the surface of T-cells, and its ligands, PD-L1 and PD-L2, found on tumor cells and immune cells. This blockade prevents the cancer cells from evading the immune response. Favezelimab targets SIGLEC-15, a protein that suppresses the immune system's ability to attack cancer cells, thereby reducing the tumor's defense mechanisms against the immune system. By inhibiting both PD-1 and SIGLEC-15, the combination therapy aims to restore and amplify the immune system's ability to fight cancer.
Clinical Trials[edit | edit source]
Clinical trials are essential for evaluating the safety, efficacy, and optimal dosing of favezelimab/pembrolizumab combination therapy in various cancer types. These studies help to determine the therapeutic potential and side effect profile of the combination, comparing it to standard treatments or placebo. As of the last update, several phase I and II clinical trials are underway or have been completed, assessing the effectiveness of this combination in treating melanoma, non-small cell lung cancer (NSCLC), and other solid tumors.
Side Effects[edit | edit source]
The side effects of favezelimab/pembrolizumab combination therapy can vary from mild to severe and are similar to those observed with other immunotherapies. Common side effects include fatigue, skin rash, diarrhea, and immune-related adverse events such as pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Management of these side effects involves close monitoring, dose adjustments, or discontinuation of therapy, and in some cases, the administration of corticosteroids or other immunosuppressive agents.
Future Directions[edit | edit source]
Research continues to explore the full potential of favezelimab/pembrolizumab combination therapy in oncology. Future studies may focus on identifying biomarkers for response, optimizing dosing schedules, and expanding the range of cancers that can be effectively treated with this combination. Additionally, research into combining these drugs with other therapeutic modalities, such as chemotherapy, targeted therapy, or other immunotherapies, is ongoing to improve outcomes for cancer patients.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD